FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912615037> ?p ?o ?g. }

• W2912615037 endingPage "2637" @default.
• W2912615037 startingPage "2637" @default.
• W2912615037 abstract "Abstract Background We showed earlier that prolonged treatment with a combination of azacitidine (DNMT1 inhibitor) and panobinostat (HDAC inhibitor) induced complete remission in a disseminated xenograft model of KMT2A rearranged AML (Gopalakrishnapillai et al., 2017, Leuk Res). Pretreatment with epigenetic drugs has been shown to induce chemo-sensitivity in some malignancies. However, studies on the use of epigenetic drugs in overcoming chemoresistance mediated by the bone marrow microenvironment are limited. The aim of this study was to determine the merit of incorporating epigenetic therapy with chemotherapy in AML treatment regimen and to identify the mechanism by which epigenetic drugs can chemosensitize AML. Methods AML cell lines and PDX lines were co-cultured with HS5 bone marrow stromal cells. Cell viability following drug treatment was assessed by flow cytometry. For determination of cell adhesion, violet proliferation dye stained AML cells were co-cultured with HS5 cells. Following treatment, non-adherent cells were removed by washes with phosphate buffered saline. The number of adherent AML cells was determined by flow cytometry. NSG-B2m mice were engrafted with MV4;11 cells and bled regularly to evaluate disease progression. Once engraftment was confirmed mice were assigned to treatment groups. Epigenetic therapy constituted azacitidine and panobinostat (2.5 mg/Kg each; Qd5). Chemotherapy constituted cytarabine (50 mg/Kg; Qd5) and daunorubicin (1.5 mg/Kg; Qd3). Mice were euthanized when they reached predetermined experimental endpoints. All animal studies were approved by the Institutional Animal Care and Use Committee. Results AML cells in co-culture with HS5 bone marrow stromal cells were less sensitive to chemotherapeutics cytarabine and daunorubicin compared to AML cells in monoculture. This chemoprotection was not achieved when AML cells were cultured in HS5 conditioned media or in Transwell inserts suspended over HS5 monolayers, suggesting that direct cell-to-cell contact was required. MV4;11 cells exposed to epigenetic drugs or cytarabine alone retained 70% viability. Pre-treatment with the epigenetic drug combination of azacitidine and panobinostat prior to cytarabine exposure greatly reduced cell viability in MV4;11 cells harboring KMT2A fusion (Fig. 1A). Similar chemo-sensitization was observed when four distinct KMT2A rearranged PDX lines were used ex vivo. This sensitization was accompanied by reduced binding of AML cells to HS5 cells following treatment with epigenetic drugs (Fig. 1B). We evaluated the efficacy of the epigenetic therapy and chemotherapy combination in disseminated xenograft models of pediatric AML. NSG-B2m mice transplanted with MV4;11 cells via the tail vein were randomly assigned to four groups - 1) vehicle, 2) epigenetic therapy 3) chemotherapy (cytarabine + daunorubicin), and 4) epigenetic therapy followed by chemotherapy. The mice receiving the epigenetic therapy and chemotherapy combination survived significantly longer than mice treated with any other condition (Fig. 1C). To assess the leukemic cell distribution in peripheral blood, bone marrow and spleen following treatment, a cohort of mice receiving epigenetic therapy alone or chemotherapy alone were euthanized a day after treatment concluded. The percentage of leukemic cells in bone marrow and spleen was lower in mice treated with epigenetic therapy than those treated with chemotherapy, consistent with the survival data. Surprisingly, the peripheral blood counts were significantly higher in mice receiving epigenetic drug combination. These results together with our in vitro data indicate that epigenetic therapy induces mobilization of AML cells to the blood stream. This increased availability of AML cells may promote enhanced sensitivity to chemotherapy. Conclusion Our data suggest that direct cell-to-cell contact plays a major role in mediating chemoprotective effects of the bone marrow microenvironment. These chemoprotective effects can be overcome by pretreatment with epigenetic drug combination azacitidine and panobinostat. Epigenetic drugs interfere with AML cell interactions with the microenvironment and dislodge AML cells from their protective niche. Thus, mobilization of AML cells to peripheral blood is a potential mechanism of chemo-sensitization mediated by epigenetic drugs. Disclosures Kolb: Servier: Membership on an entity's Board of Directors or advisory committees; Roche- Genentech: Membership on an entity's Board of Directors or advisory committees." @default.
• W2912615037 created "2019-02-21" @default.
• W2912615037 creator A5009981843 @default.
• W2912615037 creator A5038744179 @default.
• W2912615037 creator A5064118205 @default.
• W2912615037 creator A5065968475 @default.
• W2912615037 date "2018-11-29" @default.
• W2912615037 modified "2023-09-26" @default.
• W2912615037 title "Epigenetic Drug Combination Chemo-Sensitizes Pediatric AML By Reducing Cell Adhesion and Dislodging AML Cells from the Bone Marrow" @default.
• W2912615037 doi "https://doi.org/10.1182/blood-2018-99-120321" @default.
• W2912615037 hasPublicationYear "2018" @default.
• W2912615037 type Work @default.
• W2912615037 sameAs 2912615037 @default.
• W2912615037 citedByCount "0" @default.
• W2912615037 crossrefType "journal-article" @default.
• W2912615037 hasAuthorship W2912615037A5009981843 @default.
• W2912615037 hasAuthorship W2912615037A5038744179 @default.
• W2912615037 hasAuthorship W2912615037A5064118205 @default.
• W2912615037 hasAuthorship W2912615037A5065968475 @default.
• W2912615037 hasConcept C104317684 @default.
• W2912615037 hasConcept C150194340 @default.
• W2912615037 hasConcept C16930146 @default.
• W2912615037 hasConcept C190727270 @default.
• W2912615037 hasConcept C203014093 @default.
• W2912615037 hasConcept C2776239401 @default.
• W2912615037 hasConcept C2778041864 @default.
• W2912615037 hasConcept C2778305200 @default.
• W2912615037 hasConcept C2778461978 @default.
• W2912615037 hasConcept C2778729363 @default.
• W2912615037 hasConcept C2780007613 @default.
• W2912615037 hasConcept C2780225316 @default.
• W2912615037 hasConcept C2781021840 @default.
• W2912615037 hasConcept C502942594 @default.
• W2912615037 hasConcept C553184892 @default.
• W2912615037 hasConcept C55493867 @default.
• W2912615037 hasConcept C64927066 @default.
• W2912615037 hasConcept C71924100 @default.
• W2912615037 hasConcept C86803240 @default.
• W2912615037 hasConcept C98274493 @default.
• W2912615037 hasConceptScore W2912615037C104317684 @default.
• W2912615037 hasConceptScore W2912615037C150194340 @default.
• W2912615037 hasConceptScore W2912615037C16930146 @default.
• W2912615037 hasConceptScore W2912615037C190727270 @default.
• W2912615037 hasConceptScore W2912615037C203014093 @default.
• W2912615037 hasConceptScore W2912615037C2776239401 @default.
• W2912615037 hasConceptScore W2912615037C2778041864 @default.
• W2912615037 hasConceptScore W2912615037C2778305200 @default.
• W2912615037 hasConceptScore W2912615037C2778461978 @default.
• W2912615037 hasConceptScore W2912615037C2778729363 @default.
• W2912615037 hasConceptScore W2912615037C2780007613 @default.
• W2912615037 hasConceptScore W2912615037C2780225316 @default.
• W2912615037 hasConceptScore W2912615037C2781021840 @default.
• W2912615037 hasConceptScore W2912615037C502942594 @default.
• W2912615037 hasConceptScore W2912615037C553184892 @default.
• W2912615037 hasConceptScore W2912615037C55493867 @default.
• W2912615037 hasConceptScore W2912615037C64927066 @default.
• W2912615037 hasConceptScore W2912615037C71924100 @default.
• W2912615037 hasConceptScore W2912615037C86803240 @default.
• W2912615037 hasConceptScore W2912615037C98274493 @default.
• W2912615037 hasIssue "Supplement 1" @default.
• W2912615037 hasLocation W29126150371 @default.
• W2912615037 hasOpenAccess W2912615037 @default.
• W2912615037 hasPrimaryLocation W29126150371 @default.
• W2912615037 hasRelatedWork W1975473919 @default.
• W2912615037 hasRelatedWork W2029347230 @default.
• W2912615037 hasRelatedWork W2040855010 @default.
• W2912615037 hasRelatedWork W2091231814 @default.
• W2912615037 hasRelatedWork W2382885598 @default.
• W2912615037 hasRelatedWork W2410337705 @default.
• W2912615037 hasRelatedWork W2490958314 @default.
• W2912615037 hasRelatedWork W2572260531 @default.
• W2912615037 hasRelatedWork W2729031813 @default.
• W2912615037 hasRelatedWork W812818912 @default.
• W2912615037 hasVolume "132" @default.
• W2912615037 isParatext "false" @default.
• W2912615037 isRetracted "false" @default.
• W2912615037 magId "2912615037" @default.
• W2912615037 workType "article" @default.